Letter

Treatment strategies will need to be changed because of drug resistance

BMJ 1996; 313 doi: 10.1136/bmj.313.7048.45b (Published 6 July 1996)
Cite this as: BMJ 1996;313:45.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jon S Friedland,
  2. Gio Simoes
  1. Senior lecturer MSc student Department of Infectious Diseases and Bacteriology, Royal Postgraduate Medical School Hammersmith Hospital, London W12 0NN

    EDITOR,—Dale I Morse notes that the emergence of multidrug resistant Mycobacterium tuberculosis has been one of the spurs to supervised chemotherapy.1 Other aspects of treatment protocols are equally important in controlling the emergence of drug resistance. Currently, the British National Formulary recommends that standard treatment for tuberculosis should be with three drugs (isoniazid, rifampicin, and pyrazinamide). Indications for adding a fourth drug include previous default from treatment and immigration from areas of the world with a high prevalence …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular